- Home
- GNRC vs HALO Comparison
GNRC vs HALO Comparison
Compare GNRC & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNRC | HALO |
|---|---|---|
| Founded | 1959 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 11.2B |
| IPO Year | 2009 | 2001 |
Fundamental Metrics
Financial Performance| Metric | GNRC | HALO |
|---|---|---|
| Price | $184.83 | $105.45 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $211.75 | $78.64 |
| AVG Volume (30 Days) | 1.0M | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.64 | 3.11 |
| Revenue | ★ $4,209,147,000.00 | $151,862,000.00 |
| Revenue This Year | $17.36 | $28.24 |
| Revenue Next Year | $12.51 | $12.56 |
| P/E Ratio | $50.50 | ★ $33.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $134.80 | $61.23 |
| 52 Week High | $296.44 | $109.66 |
Technical Indicators
Market Signals| Indicator | GNRC | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 32.11 | 67.71 |
| Support Level | $135.53 | $67.12 |
| Resistance Level | $225.67 | N/A |
| Average True Range (ATR) | 8.02 | 2.57 |
| MACD | -1.80 | -0.59 |
| Stochastic Oscillator | 4.32 | 63.36 |
Price Performance
Historical ComparisonAbout GNRC Generac Holdlings Inc.
Generac designs and manufactures power generation equipment serving residential, commercial, and industrial markets. It offers standby generators, portable generators, lighting, outdoor power equipment, and a suite of clean energy products. Sales generated in the United States account for the majority of total sales.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.